Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
基本信息
- 批准号:9206762
- 负责人:
- 金额:$ 21.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY ABSTRACT FOR THE NVSN CORE
The purpose of this project is to support a network of US pediatric institutions to conduct prospective, active
surveillance in defined inpatient and emergency department (ED) populations for acute gastroenteritis (AGE)
and acute respiratory illnesses (ARI) and in asymptomatic healthy controls for evaluation of disease burden
and annual estimates of influenza and rotavirus vaccine effectiveness (VE). The results from this program will
be used to inform vaccine recommendations and assess the public health impact of the US rotavirus and
influenza vaccination programs and provide epidemiologic data for other infectious diseases with therapeutics
and vaccines in development. A second purpose is to prospectively follow children from birth to age two for
a natural history study of pathogens and immunologic factors related to symptomatic and asymptomatic
infection. Our proposal for this study is provided separately as an Optional Component.
The first objective is to evaluate the effectiveness and impact of current or upcoming vaccines or other
immunoprophylaxis strategies and to inform pediatric vaccine-related policies. This will be done through the
AGE and ARI active surveillance program. The rotavirus and influenza vaccine programs will be evaluated.
Children with AGE enrolled in the hospital and ED will have stool tested for rotavirus and rotavirus vaccine
verification completed. Using a test-negative design, the vaccination status of children with laboratory-
confirmed rotavirus will be compared to children testing negative for rotavirus to determine the effectiveness of
rotavirus vaccines by age and vaccine type. Children > 6 months to 18 years of age hospitalized for ARI will be
enrolled, nasal and throat swabs will be tested by influenza RT-PCR and vaccine verification will be completed.
VE estimates will be made using a test-negative study design by age, vaccine type and influenza sub-types.
The secondary objective is to actively assess the burden of AGE and ARI pathogens in pediatric hospital and
ED populations using sensitive laboratory techniques on specimens collected during the 5 years of the project.
A separate healthy control surveillance program will provide age and season frequency matched children for
comparison to ill children for both AGE and ARI pathogens. Age- and pathogen-specific population-based
estimates of incidence will be made by site and setting (hospital and ED).
A third objective is to examine the epidemiologic, host and environmental factors that are relevant for public
health interventions of vaccine preventable diseases and diseases in need of preventive or treatment strategies.
This will be done through investigator-initiated proposals through the surveillance and optional component.
This surveillance network and its associated activities will lead to high impact public health findings in the field
of vaccine preventable diseases that will ultimately contribute to strategies to reduce the overall healthcare
burden from these diseases and improve the health of the US population.
NVSN核心项目总结摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARY A STAAT其他文献
MARY A STAAT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARY A STAAT', 18)}}的其他基金
US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
美国加强监测网络评估疫苗预防儿童肠道和呼吸道病毒的负担、自然史和有效性
- 批准号:
10347720 - 财政年份:2021
- 资助金额:
$ 21.43万 - 项目类别:
US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
美国加强监测网络评估疫苗预防儿童肠道和呼吸道病毒的负担、自然史和有效性
- 批准号:
10598645 - 财政年份:2021
- 资助金额:
$ 21.43万 - 项目类别:
IP21-002 US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
IP21-002 美国增强监测网络,评估预防儿童肠道和呼吸道病毒的疫苗负担、自然史和有效性
- 批准号:
10669091 - 财政年份:2021
- 资助金额:
$ 21.43万 - 项目类别:
COVID-19 Epidemiology and Immune-Pathogenesis in Pregnant Women, Mothers and Children
COVID-19 孕妇、母亲和儿童的流行病学和免疫发病机制
- 批准号:
10213945 - 财政年份:2020
- 资助金额:
$ 21.43万 - 项目类别:
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity
初次接触流感对流感免疫的质量、程度、广度、效力和持久性的影响
- 批准号:
10394227 - 财政年份:2019
- 资助金额:
$ 21.43万 - 项目类别:
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity
初次接触流感对流感免疫的质量、程度、广度、效力和持久性的影响
- 批准号:
10614959 - 财政年份:2019
- 资助金额:
$ 21.43万 - 项目类别:
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity
初次接触流感对流感免疫的质量、程度、广度、效力和持久性的影响
- 批准号:
9925182 - 财政年份:2019
- 资助金额:
$ 21.43万 - 项目类别:
COVID-19 Epidemiology and Immune-Pathogenesis in Pregnant Women, Mothers and Children
COVID-19 孕妇、母亲和儿童的流行病学和免疫发病机制
- 批准号:
10611603 - 财政年份:2019
- 资助金额:
$ 21.43万 - 项目类别:
COVID-19 Epidemiology and Immune-Pathogenesis in Pregnant Women, Mothers and Children
COVID-19 孕妇、母亲和儿童的流行病学和免疫发病机制
- 批准号:
10265666 - 财政年份:2019
- 资助金额:
$ 21.43万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
9980742 - 财政年份:2016
- 资助金额:
$ 21.43万 - 项目类别:
相似海外基金
IP21-002 Enhanced Surveillance for New Vaccine Preventable Diseases
IP21-002 加强对新疫苗可预防疾病的监测
- 批准号:
10669094 - 财政年份:2021
- 资助金额:
$ 21.43万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
10345655 - 财政年份:2021
- 资助金额:
$ 21.43万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
10469296 - 财政年份:2021
- 资助金额:
$ 21.43万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
9763385 - 财政年份:2016
- 资助金额:
$ 21.43万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
9533884 - 财政年份:2016
- 资助金额:
$ 21.43万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
9324464 - 财政年份:2016
- 资助金额:
$ 21.43万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
9762620 - 财政年份:2016
- 资助金额:
$ 21.43万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
9980742 - 财政年份:2016
- 资助金额:
$ 21.43万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
10183093 - 财政年份:2016
- 资助金额:
$ 21.43万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
9205405 - 财政年份:2016
- 资助金额:
$ 21.43万 - 项目类别:














{{item.name}}会员




